Lactobacillus rhamnosus shows some potential benefits for IBS patients, particularly those with diarrhea-predominant IBS, but evidence is limited and mixed. More research is needed to confirm its efficacy.
A high-quality randomized controlled trial (PMID: 22563194) investigated Lactobacillus casei rhamnosus LCR35 in IBS patients and found no significant improvement in overall IBS severity compared to placebo. However, a subgroup with diarrhea-predominant IBS showed clinically relevant symptom improvement with LCR35. Other studies did not specifically evaluate Lactobacillus rhamnosus alone but used multi-strain probiotics including Lactobacillus species, showing some benefits in IBS symptom management. Meta-analyses and trials on other Lactobacillus strains (not rhamnosus) suggest probiotics may help IBS symptoms generally, but strain-specific effects vary and evidence certainty is often low to moderate. Safety profiles are generally good with few adverse events reported.
Evidence is preliminary and from a small pilot study; larger studies are needed to confirm efficacy.
Lactobacillus rhamnosus LCR35 was well tolerated with no significant adverse events reported. Probiotics in general have a good safety profile in IBS patients, including children and adults, with rare mild adverse events.
Limited number of studies specifically on Lactobacillus rhamnosus for IBS; small sample sizes in subgroup analyses; mixed results across IBS subtypes; lack of large-scale confirmatory trials; heterogeneity in probiotic strains and formulations; some evidence is low certainty due to risk of bias and inconsistency.
Probiotics.info is an educational and research platform. Its content does not constitute medical advice.
By continuing, you acknowledge our policies and agree to our Terms of Use.
Necessary cookies keep the website working. You can also allow optional cookies for analytics and referral tracking.
You can change your cookie preferences later.